FOLH1 and neoplasm: The reasons for this are, on the one hand, the large size of the tumor used for the evaluation of the efficacy in this study compared with that reported in the literature (100 mm3 vs. 20 mm3), and the fact that larger tumors are somewhat weakened by the therapeutic effect of radionuclides due to possible necrosis in their centers and the difficulty of penetration of radiation; on the other hand, the 22Rv1 cells have a lower level of PSMA expression than LNCaP and PC-3 PIP cells.